Overview of safety experience with caspofungin in clinical trials conducted over the first 15 years: A brief report

International Journal of Antimicrobial Agents

Volumn 38, Issue 6, 2011, Pages 540-544

  Ngai, Angela L ^a   Bourque, Michael R ^a   Lupinacci, Robert J ^a   Strohmaier, Kim M ^a   Kartsonis, Nicholas A ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Caspofungin; Clinical trials; Empirical therapy; Invasive mycoses; Safety

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; CYCLOSPORIN A; FLUCONAZOLE; ITRACONAZOLE; MYCOPHENOLIC ACID; NELFINAVIR; RIFAMPICIN; TACROLIMUS; VORICONAZOLE;

ADOLESCENT; ADULT; AGE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CHILD; CHILL; CREATININE BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ESOPHAGUS CANDIDIASIS; FEVER; FLUSHING; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOKALEMIA; INFANT; INFUSED VEIN COMPLICATION; INJECTION SITE PRURITUS; INJECTION SITE REACTION; INVASIVE ASPERGILLOSIS; INVASIVE CANDIDIASIS; LIVER FAILURE; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MONOTHERAPY; MULTIPLE DRUG DOSE; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; OROPHARYNX CANDIDIASIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHLEBITIS; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN URINE LEVEL; PRURITUS; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; THROMBOPHLEBITIS; UNSPECIFIED SIDE EFFECT; UREA NITROGEN BLOOD LEVEL; VOMITING;

EID: 80255131436     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2011.07.008     Document Type: Article

References (17)

1. N.A. Kartsonis, J. Nielsen, and C.M. Douglas Caspofungin: the first in a new class of antifungal agents Drug Resist Updat 6 2003 197 218 (Pubitemid 37129919)
2. C.A. Sable, B.-Y.T. Nguyen, J. Chodakewitz, and M.J. DiNubile Safety and tolerability of caspofungin acetate in the treatment of fungal infections Transpl Infect Dis 4 2002 25 30 (Pubitemid 34786821)
3. J. Mora-Duarte, R. Betts, C. Rotstein, A.L. Colombo, L. Thompson-Moya, and J. Smietana Comparison of caspofungin and amphotericin B for invasive candidiasis N Engl J Med 347 2002 2020 2029 (Pubitemid 35461658)
4. R.F. Betts, M. Nucci, D. Talwar, M. Gareca, F. Queiroz-Telles, and R.J. Bedimo A multicenter, double-blind trial of a high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasis Clin Infect Dis 48 2009 1676 1684
5. O.A. Cornely, M. Lasso, R. Betts, N. Klimko, J. Vazquez, and G. Dobb Caspofungin for the treatment of less common forms of invasive candidiasis J Antimicrob Chemother 60 2007 363 369 (Pubitemid 47243887)
6. J. Maertens, I. Raad, G. Petrikkos, M. Boogaerts, D. Selleslag, and F.B. Petersen Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy Clin Infect Dis 39 2004 1563 1571 (Pubitemid 39578526)
7. J. Maertens, A. Glasmacher, R. Herbrecht, A. Thiebaut, C. Cordonnier, and B.H. Segal Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis Cancer 107 2006 2888 2897 (Pubitemid 44937044)
8. T.E. Zaoutis, H.S. Jafri, L-M. Huang, F. Locatelli, A. Barzilai, and W. Ebell A prospective, multicenter study of caspofungin for the treatment of documented Candida or Aspergillus infections in pediatric patients Pediatrics 123 2009 877 884
9. T.J. Walsh, H. Teppler, G.R. Donowitz, J.R. Maertens, L.R. Baden, and A. Dmoszynska Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia N Engl J Med 351 2004 1391 1402
10. J. Maertens, L. Madero, A. Reilly, T. Lehrnbecher, A.H. Groll, and H.S. Jafri A randomized, double-blind, multicenter trial of caspofungin vs. liposomal amphotericin B for empirical antifungal therapy of persistently febrile neutropenic pediatric patients Pediatr Infect Dis J 29 2010 415 420
11. T.J. Walsh, P.C. Adamson, N.L. Seibel, P.M. Flynn, M.N. Neely, and C. Schwartz Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents Antimicrob Agents Chemother 49 2005 4536 4545 (Pubitemid 41552583)
12. M. Neely, H.S. Jafri, N. Seibel, K. Knapp, P.C. Adamson, and S.K. Bradshaw The pharmacokinetics and safety of caspofungin in older infants and toddlers Antimicrob Agents Chemother 53 2009 1450 1456
13. X. Sáez-Llorens, M. Macias, P. Maiya, J. Pineros, H.S. Jafri, and A. Chatterjee Pharmacokinetics and safety of caspofungin in neonates and infants less than 3 months of age Antimicrob Agents Chemother 53 2009 869 875
14. A. Villaneuva, E. Gotuzzo, E.G. Arathoon, L.M. Noriega, N.A. Kartsonis, and R.J. Lupinacci A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis Am J Med 113 2002 294 299 (Pubitemid 35287295)
15. T. Zaoutis, T. Lehrnbecher, A.H. Groll, W.J. Steinbach, H.S. Jafri, and J. Maertens Safety experience with caspofungin in pediatric patients Pediatr Infect Dis J 28 2009 1132 1135
16. J. Stone, S. Li, G. Winchell, S. Bi, P. Wickersham, and M. Schwartz Population pharmacokinetics of caspofungin in candidiasis patients 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 14-17 September 2003, Chicago, IL 2003 ASM Press Washington, DC [Abstract A-1571]
17. C.C. Li, P. Sun, Y. Dong, S. Bi, R. Desai, and M.F. Dockendorf Population pharmacokinetics and pharmacodynamics of caspofungin in pediatric patients Antimicrob Agents Chemother 55 2011 2098 2105